Pertussis Vaccine Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The pertussis vaccine market size has grown steadily in recent years. It will grow from $5.5 billion in 2024 to $5.72 billion in 2025 at a compound annual growth rate (CAGR) of 4.1%. The growth in the historic period can be attributed to disease prevalence, immunization programs, pediatric vaccination, regulatory approvals.

The pertussis vaccine market size is expected to see steady growth in the next few years. It will grow to $6.62 billion in 2029 at a compound annual growth rate (CAGR) of 3.7%. The growth in the forecast period can be attributed to booster vaccination, maternal immunization, immunization for healthcare workers, global health initiatives. Major trends in the forecast period include personalized immunization schedules, combination vaccines, vaccine equity initiatives, digital health for immunization.

Increasing childbirth rates are fueling the growth of the pertussis vaccine market. Childbirth refers to the process of delivering a baby, marking the end of pregnancy when the fetus, which has developed in the mother's uterus, begins life outside the womb. The pertussis vaccine is primarily administered to children to protect them from whooping cough and other serious, potentially life-threatening diseases. For example, in January 2023, a report from the Centers for Disease Control and Prevention, a US-based national public health agency, revealed a 1% increase in registered births in the United States, with a total of 3,664,292 births, compared to the previous year. As a result, the rising childbirth rates are driving the growth of the pertussis vaccine market.

The continuous growth of the geriatric population is anticipated to drive the expansion of the pertussis vaccine market. The geriatric population encompasses individuals in their later stages of life, typically aged 65 and older. The expanding number of older adults is a key contributor to the pertussis vaccine market. As more people enjoy longer lifespans, there is a heightened demand for pertussis vaccines to protect older individuals from this serious disease. For instance, in October 2022, the Switzerland-based World Health Organization projected that the global population of individuals aged 60 years and above is set to double by 2050, reaching 2.1 billion. Simultaneously, the number of individuals aged 80 years or older is expected to triple from 2020 to 2050, totaling 426 million. Consequently, the growing geriatric population is fostering the growth of the pertussis vaccine market.

Major enterprises engaged in the pertussis vaccine market are actively advancing innovative vaccines and securing regulatory approvals to maintain their market position. For instance, in October 2022, GSK plc., a UK-based pharmaceutical and biotechnology company, announced the U.S. Food and Drug Administration (FDA) approval of BOOSTRIX. BOOSTRIX is a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) vaccine. It is administered during pregnancy to prevent pertussis (whooping cough) in newborn infants and is administered as a single upper arm muscle injection. Boostrix is recognized for its safety and effectiveness in pregnant women and their infants, effectively preventing pertussis, including severe cases of the disease.

In May 2022, GSK plc., a UK-based pharmaceutical and biotechnology company, completed the acquisition of Affinivax Inc. for a sum of $2.1 billion. This strategic acquisition is a step taken by GSK to broaden its vaccine portfolio, enhance its outreach to patients, bolster its vaccine research and development pipeline, gain access to a potentially groundbreaking technology, and expand its scientific presence in the Boston region. Affinivax Inc. is a U.S.-based biotechnology enterprise specialized in the development of pertussis vaccines.

Major companies operating in the pertussis vaccine market are Pfizer Inc., Johnson And Johnson Pvt Ltd., Merck And Co. Inc., Novartis AG, GlaxoSmithKline PLC, AstraZeneca PLC, BioNTech SE, Moderna Inc., Sinovac Biotech Ltd., CSL Limited, Astellas Pharma US Inc., Sanofi Pasteur SA, Mitsubishi Tanabe Pharma America Inc., PT Kalbe Farma Tbk, CSL Seqirus, Walvax Biotechnology Co.Ltd., Biological E. Limited, Serum Institute of India, Bavarian Nordic AS, PT Bio Farma, Bharat Biotech International Limited, Takeda Pharmaceutical Company, Panacea Biotec Limited, Beijing Minhai Biotechnology Co. Ltd., Protein Sciences Corporation, Wuhan Institute of Biological Products, Changchun Changsheng Life Sciences, Changsheng Bio-Technology Co. Ltd., Gennova Biopharmaceuticals Ltd., Chiron Corporation.

North America was the largest region in the pertussis vaccine market in 2024. The regions covered in pertussis vaccine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pertussis vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pertussis vaccine market consists of sales of adacel, daptacel, infanrix, kinrix, pediarix, pentacel and quadracel. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The pertussis vaccine is a vaccination designed to provide protection against whooping cough (pertussis), a highly contagious respiratory disease caused by the bacterium Bordetella pertussis. Its purpose is to stimulate the immune system to generate protective antibodies against the pertussis bacterium, thus reducing the risk of infection and the associated symptoms.

The main products related to the pertussis vaccine include the DTaP (diphtheria, tetanus, and acellular pertussis) vaccine and the Tdap (tetanus, diphtheria, and pertussis) vaccine. The DTaP vaccine, which is also known as the DTP vaccine, is a combination vaccine intended to safeguard against three serious bacterial infections such as diphtheria, tetanus, and pertussis (whooping cough). These vaccines are available in both whole-cell and acellular formulations and are administered to individuals of various age groups, including children, adults, and infants. They are typically administered by healthcare professionals at vaccination centers, hospitals, and clinics.

The pertussis vaccine market research report is one of a series of new reports that provides pertussis vaccine market statistics, including pertussis vaccine industry global market size, regional shares, competitors with a pertussis vaccine market share, detailed pertussis vaccine market segments, market trends and opportunities and any further data you may need to thrive in the pertussis vaccine industry. This pertussis vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.